Topic

Third Rock Ventures

A collection of 1 issue

Maze Therapeutics Reports First Profit in 2024 IPO Filing

Maze Therapeutics, backed by Third Rock Ventures, reports its first profit for the first nine months of 2024 in its U.S. IPO filing. Explore Maze Therapeutics' financial growth.